glp-1 hfpef receptor agonists, including semaglutide (Wegovy/Ozempic) and tirzepatide (Mounjaro/Zepbound), are being recognized for benefits beyond blood sugar control and weight management. New real-world evidence suggests they may also play a role in GLP-1 Receptor Agonists in Heart

The bottom line Ozempic has helped a growing number of people manage their diabetes and shed some excess weight, which also helps with their diabetes management

Informed consent : If you were not properly informed about the risks associated with using Ozempic off-label, you might have a claim based on lack of informed consent

Brookshire: Find these drugs extraordinarily compelling

Al-Kuraishy HM, Al-Gareeb AI, Alexiou A et al (2022a) 5-HT/CGRP pathway and Sumatriptan role in Covid-19

Traditionally used in diabetes and obesity treatments, GLP-1 receptor agonists (GLP-1 RAs) like Ozempic and Wegovy have gained attention for their broader health benefits